Obesity, Hypertension Linked to Kidney Cancer Development

Article

Results from two large cohorts indicated that increasing blood pressure levels were associated with an increased risk for developing kidney cancer among both men and women.

Results from two large cohorts indicated that increasing blood pressure levels were associated with an increased risk for developing kidney cancer among both men and women. The data were taken from more than 150,000 participants in the Women’s Health Initiative (WHI) and more than 350,000 men in the Multiple Risk Factor Intervention Trial (MRFIT).

“Additional prospective studies are needed to determine whether treatment and control of hypertension can reduce the risk of kidney cancer and if so, whether specific drug therapies would differ in preventive efficacy,” Kristen M. Sanfilippo, MD, of the department of hematology at Washington University, St. Louis, and colleagues wrote in Hypertension.

In the participants in the WHI, followed for a median of 15 years, 407 incident kidney cancers were diagnosed. Data indicated that the incidence of kidney cancer significantly increased with increasing systolic and diastolic blood pressure, previous hypertension diagnosis or treatment, and higher body mass index and waist circumference categories.

Specifically, the researchers found that women with a systolic blood pressure between 120.1 to 130 mm Hg had a 33% increased kidney cancer incidence compared with women with a systolic pressure of 120 mm Hg or less (HR = 1.33; 95% CI, 1.01-1.75). In addition, a diastolic blood pressure of 90 mm Hg or greater was also independently associated with kidney cancer (HR = 1.56; 95% CI, 1.06-2.29).

When the researchers stratified the patients by BMI and adjusted for age, smoking, and race/ethnicity, they found that kidney cancer risk associated with elevated systolic blood pressure was found within each strata of BMI. However, the link was only consistently significant for women with a BMI of 30 or greater. Similarly, women with the highest waist circumferences (> 97.9 cm) had almost twice the risk for kidney cancer (HR = 1.91; 95% CI, 1.38-2.63). 

Men in the MRFIT study were followed for 25 years, during which 906 deaths from kidney cancer occurred. Data indicated that men who died of kidney cancer had a greater systolic blood pressure at study entry compared with those who did not die.

The risk for dying from kidney cancer increased with increasing blood pressure levels even among patients with levels considered to be normal. Men with a systolic blood pressure of less than 120 mm Hg had about a 29% increased risk for dying from kidney cancer; whereas, men with a systolic pressure greater than 160 mm Hg had an 87% increased risk for kidney cancer death. The link between baseline diastolic blood pressure and kidney cancer mortality was not as strong.

The researchers also found an increased risk for kidney cancer death among cigarette smokers (HR = 1.75; 95% CI, 1.53-2.00; P = .0001). Among those who died from the disease, 45.5% reported smoking cigarettes at study entry. As expected, the risk for kidney cancer death was lowest among nonsmokers with a systolic blood pressure of less than 120 mm Hg.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Related Content